(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Top 10 Books That Will Adjust Your Viewpoint - 2Vote in favor of the blossom plan that adds a hint of excellence to your life!
- 3All that You Really want to Be aware of Dental Inserts Facilities
- 4Instructions to Floss Appropriately and Forestall Gum Sickness
- 521 Incredibly Entertaining Contemplations To Observe Consistently
- Embrace the Outside: Exercises and Entertainment
- Pick Your Top Method for starting the Morning
- The Best Games On the planet
- Wizz CEO: We’re going to invest $1 b. in Israeli market
- Greece eyes migrant repatriation centres outside the EU
- The Best Games Crossroads in History
- Instructions to Plan for Your Teeth Substitution Methodology
- PA accuses Israel of 'human trafficking' after planeload of Gazans arrives in South Africa
- The Way to Recuperation: Defeating Dependence
